Published in Leuk Lymphoma on November 01, 2006
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol (2008) 0.90
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol (2011) 0.79
Myeloma, thalidomide and thrombosis. Leuk Lymphoma (2006) 0.75
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol (2012) 2.94
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care (2009) 2.34
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood (2011) 2.11
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol Methods (2012) 2.01
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood (2010) 1.89
Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.53
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun (2007) 1.53
Q-learning: a data analysis method for constructing adaptive interventions. Psychol Methods (2012) 1.51
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood (2012) 1.46
A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients. Crit Care (2009) 1.45
NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44
Young adult educational and vocational outcomes of children diagnosed with ADHD. J Abnorm Child Psychol (2013) 1.43
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol (2006) 1.39
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res (2011) 1.38
The academic experience of male high school students with ADHD. J Abnorm Child Psychol (2011) 1.37
Two-sample density-based empirical likelihood tests for incomplete data in application to a pneumonia study. Biom J (2011) 1.34
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. J Clin Pathol (2011) 1.32
Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res (2008) 1.32
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood (2011) 1.24
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med (2011) 1.22
Late adolescent and young adult outcomes of girls diagnosed with ADHD in childhood: an exploratory investigation. J Atten Disord (2010) 1.19
Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.18
Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev (2006) 1.14
Two-sample nonparametric likelihood inference based on incomplete data with an application to a pneumonia study. Biom J (2010) 1.11
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10
Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol (2010) 1.10
Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant (2007) 1.10
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol (2009) 1.08
Efficacy of family-based weight control program for preschool children in primary care. Pediatrics (2012) 1.08
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer (2012) 1.06
Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology (2007) 1.06
DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res (2006) 1.04
Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol (2006) 1.02
CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol (2011) 1.01
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol (2010) 0.98
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol (2010) 0.98
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood (2010) 0.98
Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol (2012) 0.97
Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology (2004) 0.96
Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol (2004) 0.96
Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer (2006) 0.95
Targeting aurora kinases in cancer treatment. Curr Drug Targets (2011) 0.93
Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer (2005) 0.93
Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res (2004) 0.92
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res (2006) 0.92
Regular analgesic use and risk of multiple myeloma. Leuk Res (2006) 0.91
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol (2004) 0.90
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother (2010) 0.90
A waitlist-controlled trial of behavioral parent training for fathers of children with ADHD. J Clin Child Adolesc Psychol (2012) 0.90
Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma (2005) 0.88
Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol (2011) 0.87
CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg (2007) 0.87
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma (2009) 0.87
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol (2013) 0.86
Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood. Atherosclerosis (2013) 0.86
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther (2009) 0.85
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol (2015) 0.85
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2008) 0.84
Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther (2003) 0.83
Nonclinical factors associated with primary care physicians' ordering patterns of magnetic resonance imaging/computed tomography for headache. Acad Radiol (2004) 0.83
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma (2011) 0.83
Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol (2011) 0.83
Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 0.82
Women with Childhood ADHD: Comparisons by Diagnostic Group and Gender. J Psychopathol Behav Assess (2011) 0.82
High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radic Biol Med (2006) 0.82
A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer (2002) 0.80
The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation. Mol Cancer Res (2012) 0.80
Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs (2010) 0.80
Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology (2007) 0.80
Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leuk Lymphoma (2007) 0.80
Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther (2011) 0.79
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol (2011) 0.79
Cancer- and treatment-related anemia. J Natl Compr Canc Netw (2005) 0.79
Analysis of cigarette purchase task instrument data with a left-censored mixed effects model. Exp Clin Psychopharmacol (2013) 0.79
Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol (2011) 0.79
Cystic pancreatic tumors (CPT): predictors of malignant behavior. J Surg Oncol (2007) 0.78
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol (2011) 0.78
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anticancer Drugs (2008) 0.78
Evaluations and comparisons of treatment effects based on best combinations of biomarkers with applications to biomedical studies. J Comput Biol (2014) 0.77
Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer (2007) 0.76
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol (2014) 0.76
Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma (2009) 0.76
A comparison of races and leukemia subtypes among patients in different cancer survivorship phases. Clin Lymphoma Myeloma Leuk (2011) 0.76
HLA-identical sibling stem-cell transplantation in first-remission AML. Blood (2007) 0.75
Review: erythroleukemia: clinical course and management. Clin Adv Hematol Oncol (2010) 0.75
Computing Critical Values of Exact Tests by Incorporating Monte Carlo Simulations Combined with Statistical Tables. Scand Stat Theory Appl (2014) 0.75
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma (2005) 0.75
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART. HIV Clin Trials (2004) 0.75